Journal of the National Cancer Institute Advance Access originally published online on February 10, 2009
JNCI Journal of the National Cancer Institute 2009 101(4):277; doi:10.1093/jnci/djn473
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press.
CORRESPONDENCE |
Re: Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers
Affiliations of authors: Department of Oncogenetics, Prevention and Screening, INSERM UMR912, Institut Paoli-Calmettes, Marseille, France (FE, LH)
Correspondence to: Francois Eisinger, MD, Institut Paoli-Calmettes, INSERM UMR912, 232 Blvd Sainte Marguerite BP 156, 13273 Marseille Cedex 9, France (e-mail: francois.eisinger@inserm.fr).
| The first 10% of the full text of this article appears below. |
The contribution of Eisen et al. (1) to the risk mitigation associated with hormone therapy (HT) in menopaused BRCA1 mutation carriers is critical because it will help women reach an informed decision about a tough situation, balancing disease risk and quality of life. These data are also